Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
23 November 2020Website:
http://www.23andme.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:59:57 GMTDividend
Analysts recommendations
Institutional Ownership
ME Latest News
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health's clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.
NEW YORK, NY / ACCESSWIRE / June 14, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
23andMe will partner with the Colorectal Cancer Alliance on a project to advance knowledge of colorectal cancer in the Black/African American community. Participants in the study will receive 23andMe+ Premium membership at no cost.
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
NEW YORK, NY / ACCESSWIRE / June 3, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Findings from 23andMe research on Parkinson's disease published in Brain Findings from 23andMe research on Parkinson's disease published in Brain
23andMe Holding Co. (NASDAQ:ME ) Q4 2024 Earnings Conference Call May 24, 2024 4:30 PM ET Company Participants Ian Cooney - Senior Director of Investor Relations Joe Selsavage - Chief Financial Officer and Chief Accounting Officer Anne Wojcicki - Chief Executive Officer and Co-Founder Jennifer Low - Head of Therapeutics Development Conference Call Participants David Lebowitz - Citi Steven Mah - TD Cowen Operator Hello, and welcome to 23andMe's Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results Conference Call. As a reminder this call is being recorded.
What type of business is 23andMe Holding Co?
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
What sector is 23andMe Holding Co in?
23andMe Holding Co is in the Healthcare sector
What industry is 23andMe Holding Co in?
23andMe Holding Co is in the Diagnostics & Research industry
What country is 23andMe Holding Co from?
23andMe Holding Co is headquartered in United States
When did 23andMe Holding Co go public?
23andMe Holding Co initial public offering (IPO) was on 23 November 2020
What is 23andMe Holding Co website?
https://www.23andme.com
Is 23andMe Holding Co in the S&P 500?
No, 23andMe Holding Co is not included in the S&P 500 index
Is 23andMe Holding Co in the NASDAQ 100?
No, 23andMe Holding Co is not included in the NASDAQ 100 index
Is 23andMe Holding Co in the Dow Jones?
No, 23andMe Holding Co is not included in the Dow Jones index
When does 23andMe Holding Co report earnings?
The next expected earnings date for 23andMe Holding Co is 08 August 2024